F. Cosentino
Endocrinology, Diabetes and Metabolism · 2003–2021
A researcher in the Science corpus: 10 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Endocrinology, Diabetes and Metabolism — 269 citations into it
- Surgery — 184 citations into it
- Radiology, Nuclear Medicine and Imaging — 46 citations into it
- Cancer Research — 26 citations into it
Whom F. Cosentino trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from F. Cosentino's perspective
Ordered by how strongly the researchers F. Cosentino trusts endorse each paper. Same corpus, a different order for every researcher.
- Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. (Diabetes Care)
- Glucose control and vascular complications in veterans with type 2 diabetes. (New England Journal of Medicine)
- 10-year follow-up of intensive glucose control in type 2 diabetes. (New England Journal of Medicine)
- Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. (New England Journal of Medicine)
- Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. (Archives of Internal Medicine)
- EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- Eplerenone in patients with systolic heart failure and mild symptoms. (New England Journal of Medicine)
Their papers
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. (2019) — 3,193 citations
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. (2021) — 5,029 citations
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. (2020) — 1,094 citations
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes (2020) — 961 citations
- The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. (2019) — 1,498 citations
- Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology (2018) — 597 citations
- The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. (2015) — 714 citations
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I (2013) — 1,888 citations
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013) — 612 citations
- Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I (2003) — 1,136 citations